×

A path to conquering cancer: NantKwest CEO

2:23 PM ET Tue, 28 July 2015

Immunotherapy biotech company NantKwest shares opened at $37 in their trading debut, 48% above their IPO price. Patrick Soon-Shiong ,NantKwest CEO, discusses the company and success toward fighting cancer with "natural killers"